AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat
Investor's Business DailyAbbVie stock edged higher Wednesday after the pharma behemoth’s new king in immunology finally outpaced its grandfather drug, Humira.
The post AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat appeared first on Investor's B…